---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Prevalence"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Prevalence. Topics: Epidemiology, Prevalence and incidence: systematic literature review, Pooled diagnosed annual prevalence: combined HAE types and 95% confidence interval, Pooled diagnosed annual prevalence by HAE type and by region, and 8 further topics. 12 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/prevalence"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Prevalence

<a id="heading-2.2.1.2.2"></a>

## 2.2.1.2.2 Prevalence of Hereditary angioedema

<a id="topic-2.2.1.2.2-1"></a>

### Epidemiology

> “Hereditary angioedema is estimated to affect 1 in 50,000 people worldwide.”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.2.2-2"></a>

### Prevalence and incidence: systematic literature review

> “Diagnostic methodology varied greatly, with a minority of studies citing an established guideline.”

Source: [Craig et al. (2026b)](https://karger.com/iaa/article/doi/10.1159/000553023/953095/Prevalence-and-Incidence-of-Hereditary-Angioedema)

<a id="topic-2.2.1.2.2-3"></a>

### Pooled diagnosed annual prevalence: combined HAE types and 95% confidence interval

> “1.70 per 100,000 (1.58–1.83; combined types).”

Source: [Craig et al. (2026b)](https://karger.com/iaa/article/doi/10.1159/000553023/953095/Prevalence-and-Incidence-of-Hereditary-Angioedema)

<a id="topic-2.2.1.2.2-4"></a>

### Pooled diagnosed annual prevalence by HAE type and by region

> “Pooled diagnosed annual prevalence estimates (95% confidence interval) were 1.31 per 100,000 (0.83–2.08; type I HAE), 0.20 per 100,000 (0.14–0.29; type II HAE), 0.06 per 100,000 (0.01–0.40; HAE with normal C1-inhibitor [INH])”
> “Pooled estimates by region were 1.43 per 100,000 (0.99–2.08) and 1.64 per 100,000 (1.02–2.64) in North America and Europe, respectively, which were higher than individual estimates from the other regions.”

Source: [Craig et al. (2026b)](https://karger.com/iaa/article/doi/10.1159/000553023/953095/Prevalence-and-Incidence-of-Hereditary-Angioedema)

<a id="topic-2.2.1.2.2-5"></a>

### United States prevalence of all HAE types: commercial claims database, 2018 to 2020

> “No US prevalence for all types of HAE has been estimated.”
> “For 2018, 2019, and 2020, the claims-based algorithm yielded overall annual unadjusted HAE prevalence estimates per 100,000 and number of people diagnosed with HAE of 2.67, 9559; 2.61, 9341; and 2.43, 8694, respectively.”
> “The corresponding estimates based on expert physician analysis were 2.13, 7602; 2.03, 7275; and 1.84, 6595, respectively.”
> “Our calculations (which exceed the frequently cited 2:100,000 prevalence for HAE with C1 inhibitor deficiency) afford a real-world projected prevalence encompassing all types of HAE.”

Source: [Castaldo et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40414286/)

<a id="topic-2.2.1.2.2-6"></a>

### Worldwide pooled prevalence: systematic review and meta-analysis of 24 studies

> “Twenty-four studies from 2000 to 2024 were included in the analysis, describing 11,245 cases of HAE.”
> “The pooled prevalence of HAE was 1.22 cases per 100,000 people (95% confidence interval [CI]: 0.91, 1.53), with lower prevalences reported in Asia and Africa compared to Europe and North America.”
> “HAE type 1 made up most of the cases, with a slight female predominance.”

Source: [Fisch et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39827848/)

<a id="topic-2.2.1.2.2-7"></a>

### Prevalence of diagnosed HAE type 1 and 2: Finnish national register

> “The prevalence of HAE-1/2 patients increased over the follow-up time from 0.8 to 2.6/100,000 persons, equalling 144 patients at the end of 2021.”
> “The prevalence of 2.6 per 100,000 at the end of 2021 in Finland is higher than the 1.5 per 100,000 that has been observed in the other Nordic countries including Sweden, Denmark, and Norway”

Source: [Sandberg et al. (2024)](https://medicaljournalssweden.se/actadv/article/download/24176/46018/110086)

<a id="topic-2.2.1.2.2-8"></a>

### Minimum prevalence of HAE types 1 and 2: United Kingdom survey of 37 centers

> “The survey identified 1152 patients with HAE-1/2 (58% female and 92% type 1), 22 patients with HAE with normal C1 inhibitor, and 91 patients with acquired C1 inhibitor deficiency.”
> “Data were provided by 37 centers across the United Kingdom.”
> “This gives a minimum prevalence of 1:59,000 for HAE-1/2 and 1:734,000 for acquired C1 inhibitor deficiency in the United Kingdom.”

Source: [Yong et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37146882/)

<a id="topic-2.2.1.2.2-9"></a>

### Minimal prevalence in the Asia Pacific region: survey of 12 countries and territories

> “Completed questionnaires were received from 14 representatives of 12 member countries and territories, representing 46% of the world population.”
> “Overall minimal prevalence of HAE in the AP region was 0.02/100,000 population, with significant heterogeneity across different centers.”

Source: [Li et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36584968/)

<a id="topic-2.2.1.2.2-10"></a>

### Population prevalence of HAE with C1-INH deficiency: South Australia, 2021 to 2022

> “Case ascertainment was conducted over 18 months from January 2021 to July 2022, using a range of approaches with the aim of identifying all people with C1INH-HAE in South Australia.”
> “We identified 35 people with HAE in South Australia, yielding a population prevalence of 1 in 52,400, in line with average established international prevalence.”
> “There are relatively few systematic population prevalence studies, with reports from various countries of between 1 in 20,000 and 1 in 150,000.”

Source: [Troelnikov et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11239692/)

<a id="topic-2.2.1.2.2-11"></a>

### Company statement: HAE prevalence worldwide, in the United States, and in the European Union

> “According to HAE International, as of October 2014, HAE affected from 1:30,000 to 1:80,000 individuals globally, or at least 7,000 patients in the U.S. and at least 15,000 patients in the EU.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.2.1.2.2-12"></a>

### Company statement: prevalence by type of bradykinin-mediated angioedema

> “HAE-C1INH affects 1:50,000 individuals globally, HAE-nC1INH affects 1:250,000 individuals globally, and AAE-C1INH affects 1:500,000 individuals globally.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
